Payment overview · 2025
General Payments
$421.94
18 reported records · 8 companies
Healthcare provider profile · identity verified
Mitchell B. Shear, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITE PLAINS, NY · NPI 1801952510
Verified facts
What the public records show
CMS Open Payments records show Mitchell B. Shear, MD received $421.94 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $181.84 | 43.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.70 | 24.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.04 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.72 | 6.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.40 | 5.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.18 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.03 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.03 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $421.94 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $181.84 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $104.70 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.70 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 746 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 452 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 372 | 42 |
| Lisinopril | Lisinopril | 341 | 61 |
| Oxycodone Hcl | Oxycodone Hcl | 271 | 24 |
| Omeprazole | Omeprazole | 268 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 45 |
| Gabapentin | Gabapentin | 243 | 42 |
| Losartan Potassium | Losartan Potassium | 243 | 42 |
| Metformin Hcl | Metformin Hcl | 226 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 23 |
| Famotidine | Famotidine | 183 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 19 |
| Eliquis | Apixaban | 156 | 27 |
| Ezetimibe | Ezetimibe | 153 | 21 |
| Alprazolam | Alprazolam | 152 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 18 |
| Prednisone | Prednisone | 128 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 33 |
| Levetiracetam | Levetiracetam | 118 | 17 |
| Nifedipine Er | Nifedipine | 118 | 19 |
| Memantine Hcl | Memantine Hcl | 114 | suppressed |
| Januvia | Sitagliptin Phosphate | 104 | 18 |
| Jardiance | Empagliflozin | 102 | 17 |
| Mirtazapine | Mirtazapine | 96 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 93 | 12 |
| Ozempic | Semaglutide | 92 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | suppressed |
| Carvedilol | Carvedilol | 89 | 17 |
| Chlorthalidone | Chlorthalidone | 87 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 21 |
| Furosemide | Furosemide | 81 | 17 |
| Baclofen | Baclofen | 80 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 13 |
| Simvastatin | Simvastatin | 78 | 14 |
| Ibuprofen | Ibuprofen | 74 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 11 |
| Lactulose | Lactulose | 71 | 17 |
| Trazodone Hcl | Trazodone Hcl | 71 | 17 |
| Alendronate Sodium | Alendronate Sodium | 70 | 12 |
| Tramadol Hcl | Tramadol Hcl | 70 | 14 |
| Divalproex Sodium | Divalproex Sodium | 66 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 63 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 62 | 17 |
| Sertraline Hcl | Sertraline Hcl | 61 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 59 | 20 |
| Allopurinol | Allopurinol | 56 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 52 | suppressed |
| Latanoprost | Latanoprost | 51 | suppressed |
| Finasteride | Finasteride | 50 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 49 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 11 |
| Methimazole | Methimazole | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Atenolol | Atenolol | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 12 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 28 | suppressed |
| Nystatin | Nystatin | 28 | 12 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Etravirine | Etravirine | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Tivicay | Dolutegravir Sodium | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.94 · 18 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CAPLYTA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VOWST, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error